Pharmaniaga Berhad ("Pharmaniaga" or "the Group") wishes to clarify recent media reports on 13 November 2025 regarding the Group’s financial results for the period ended 30 September 2025 (Q3 FY2025), announced to Bursa Malaysia yesterday.

For Q3 FY2025, the Group recorded a Profit After Tax (PAT) of RM7.5 million. While this reflects a decrease from RM101.3 million in the corresponding quarter last year, the prior period included a one-off penalty waiver of RM94.9 million (net of tax) from the Government. The penalty waiver was related to Pharmaniaga Logistics Sdn Bhd’s non-fulfilment of certain performance standards specified in the previous concession agreement, caused by Movement Control Order during the COVID-19 pandemic period.

Excluding the one-off penalty waiver of RM124.9 million in the previous financial year, the Group recorded a solid underlying revenue growth of 11.3% compared with the corresponding quarter last year. Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) for Q3 FY2025 stood at RM32.7 million, indicating stable underlying profitability.

Overall, the Group delivered stronger performance in Q3 FY2025 compared to the previous year, underpinned by enhanced operational efficiencies, disciplined cost optimisation efforts, and the absence of one-off item in the current reporting period.

We trust this provides clarity on the differences in the reported results.

This announcement is dated 14 November 2025.